MindWalk Validates Platform Precision with Breakthrough Discovery Targeting Pathogenic TDP-43 in Neurodegenerative Disease
MindWalk Holdings Corp. (HYFT)
Company Research
Source: Business Wire
VICTORIA, British Columbia--(BUSINESS WIRE)--MindWalk Holdings Corp. (“MindWalk” or the “Company”) (Nasdaq: HYFT) today announced the discovery and validation of monoclonal antibodies and intrabodies that selectively target misfolded, pathogenic TDP-43, a disease-driving protein implicated in amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and certain forms of Alzheimer’s disease.The work demonstrates MindWalk’s ability to discriminate with structural precision between toxic protein conformations and their healthy counterparts, a long-standing challenge in neurodegenerative drug development. By defining the disease-driving structural state and anchoring it in bio-native wet-lab validation, the Company is resolving both the structural and functional logic of neurodegeneration and converting that understanding into selective, evidence-linked biological assets.“This discovery validates our platform strategy,” said Dr. Jennifer Bath, President and Chief Executive O
Show less
Read more
Impact Snapshot
Event Time:
HYFT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HYFT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HYFT alerts
High impacting MindWalk Holdings Corp. news events
Weekly update
A roundup of the hottest topics
HYFT
News
- MindWalk (NASDAQ:HYFT) is now covered by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>. They set a "sell (d-)" rating on the stock.MarketBeat
- MindWalk (NASDAQ:HYFT) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.MarketBeat
- REPEAT/MindWalk Advances Universal Influenza Program with a Breakthrough Functional InsightBusiness Wire
- MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight [Yahoo! Finance]Yahoo! Finance
- MindWalk Advances Universal Influenza Program with a Breakthrough Functional InsightBusiness Wire
HYFT
Earnings
- 12/15/25 - Miss
HYFT
Sec Filings
- 1/14/26 - Form 6-K
- 1/12/26 - Form 6-K
- 12/15/25 - Form 6-K
- HYFT's page on the SEC website